Beyond Health Canada Approval: How CADTH's HTA Process Determines Whether Canadians Can Access Your Drug

Most pharmaceutical sponsors treat Canadian market access as a two-step sequence: get Health Canada approval, then launch. That assumption costs some companies years of lost revenue — and in some cases, means their drug never reaches a single patient covered by a public drug plan.

Canada has a parallel, non-trivial reimbursement evaluation process administered by the Canadian Drug and Health Technology Agency — CADTH. A positive Notice of Compliance (NOC) from Health Canada tells you your drug is safe and effective enough to sell in Canada. It says nothing about whether provincial or federal drug plans will actually pay for it.

For the vast majority of drugs targeting publicly insured patient populations, CADTH’s Common Drug Review (CDR) is the gate that matters commercially.

What CADTH Does — and What It Has Nothing To Do With

CADTH was established in 1989 and operates at arm’s length from the federal government. It provides health technology assessments to 18 public drug plans across Canada — including federal programs like the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit, Correctional Service Canada, the Canadian Armed Forces, and the Royal Canadian Mounted Police, alongside most provincial and territorial formularies. Quebec administers its own parallel system through INESSS (Institut national d’excellence en santé et en services sociaux), which means sponsors targeting full pan-Canadian coverage must navigate two separate HTA processes.

CADTH does not approve or reject drugs. It issues recommendations to payers: Reimburse, Reimburse with conditions (RwC), or Do Not Reimburse. Individual drug plans aren’t legally bound by these recommendations — but in practice, a “Do Not Reimburse” recommendation almost universally means the drug won’t reach provincial formularies. A conditional recommendation can result in reimbursement tied to specific patient eligibility criteria, mandatory step therapy requirements, or confidential price conditions negotiated separately.

The oncology review function, formerly called the pan-Canadian Oncology Drug Review (pCODR), is now fully integrated under CADTH’s umbrella. The process carries procedural differences from the CDR — including a mandatory patient advocacy group input stage that carries real deliberative weight — but the underlying evidence framework is similar.

The CDR Submission Package: What You’re Actually Building

A CDR submission is not a reformatted New Drug Submission. It’s a distinct dossier with components that Health Canada never reviews. Sponsors routinely underestimate this gap, particularly those whose regulatory teams have US or EU experience, where market authorization and reimbursement are handled by separate institutions with entirely different expectations.

A standard CDR submission includes four core components.

Clinical Evidence Package. This follows CADTH’s CDR Submission Guidelines and requires a systematic literature review, pooled analyses where evidence supports them, and — critically — an indirect treatment comparison (ITC) if no head-to-head trials exist against the relevant Canadian comparators. The comparator selection is among the most consequential decisions a sponsor makes in the CDR process. CADTH uses what’s clinically relevant and currently reimbursed in Canada, which often differs from the comparators used in pivotal trials designed for FDA or EMA submissions.

Pharmacoeconomic Evidence Package. CADTH requires a Canadian-specific model prepared in accordance with the CADTH Guidelines for the Economic Evaluation of Health Technologies. Unlike the UK’s NICE — which publishes a willingness-to-pay threshold of £20,000–£30,000 per quality-adjusted life year (QALY) — CADTH evaluates incremental cost-effectiveness ratios (ICERs) within a broader value framework without a fixed threshold. That ambiguity is deliberate. It means the internal logic and plausibility of your model matter enormously, not just the headline ICER. Canadian utility values, Canadian resource costs, and Canadian epidemiology data are all expected. Lifting a pharmacoeconomic model from a US or EU dossier and adjusting the currency symbol is a near-guarantee of a CADTH addendum request.

Budget Impact Model (BIM). Sponsors must estimate the net budgetary impact on Canadian public payers over a 3-year time horizon. CADTH reviews the structural assumptions carefully and runs its own sensitivity analyses. If your market share projections look optimistic relative to existing treatment uptake patterns or epidemiological data, expect pointed questions.

Patient Input. CADTH formally solicits input from registered patient groups and incorporates it into committee deliberations. Since 2017, this process has become more structured and consequential. Patient groups complete a standardized template covering disease burden, current treatment gaps, and outcomes that matter most to patients — not just what appeared in the primary endpoints of your trial. Sponsors who haven’t built relationships with relevant patient advocacy organizations before filing start the process at a meaningful disadvantage.

Realistic Timelines: From NOC to Formulary

The CDR’s target review period is approximately 24–26 weeks from when CADTH accepts a complete submission. That sounds manageable until you stack the full market access timeline:

• Pre-submission preparation: 6–12 months post-NOC for sponsors who deprioritized health economic modelling during development
• CDR or pCODR review: 24–26 weeks from acceptance
• pCPA negotiations: 12–18 months on average after a positive CADTH recommendation — some negotiations extend beyond 24 months
• Provincial formulary listing: 90–180 days after pCPA completion, varying significantly by province

In a realistic scenario, a sponsor receiving an NOC in early 2024 might not see reimbursement in major provincial formularies until late 2027 or 2028. That’s not an outlier — it reflects the modal experience for novel therapeutics in Canada. Oncology drugs can move faster due to pCODR process efficiencies and managed access programs that provincial ministries can activate while formal reimbursement is pending, but these are not guaranteed and typically require proactive sponsor engagement with provincial cancer agencies.

Five Things That Sink CDR Submissions

After reviewing CADTH recommendations and the deficiency correspondence that precedes many of them, certain failure patterns recur.

Wrong comparator. Canadian standard of care does not always mirror US or European practice. If pivotal trials used a comparator not reimbursed as first-line therapy in Canada, CADTH will flag it — and may request an ITC your team hasn’t modelled and your clinical data aren’t powered to support well.

Missing or misspecified Canadian utilities. Utility values derived from European or American trial populations, applied without Canadian-specific validation, weaken the health-economic argument. CADTH reviewers conduct independent systematic reviews of utility literature and flag discrepancies with the model’s inputs.

Aggressive market share assumptions in the BIM. If the budget impact model assumes rapid, broad uptake in a segment where existing therapies are entrenched and demonstrated unmet need is limited, the model fails the plausibility test. CADTH’s sensitivity analyses will surface this.

No patient advocacy engagement. CADTH’s registered patient groups for each CDR are publicly listed. Sponsors who engage them early — before submission, ideally during Phase III — get patient input sections that reinforce clinical evidence. Sponsors who engage late risk patient input that introduces uncertainty CADTH’s committee wasn’t expecting.

Treating the CDR as a regulatory exercise. CDR dossiers require health economist expertise, not just regulatory affairs professionals. The strongest submissions are co-designed by market access specialists, health economists, and regulatory teams working together from the outset — not handing off sequentially after the NOC lands.

The INESSS Dimension Sponsors Often Overlook

Quebec’s INESSS operates on a separate legislative basis from CADTH and uses its own evidence standards. It evaluates drugs for listing on the Liste des médicaments (the provincial formulary) and publishes its own recommendations. INESSS and CADTH sometimes reach different conclusions on the same drug. Sponsors who plan their Canadian market access strategy around a CADTH recommendation alone, then assume Quebec follows automatically, are misreading the system.

Parallel CADTH and INESSS submissions are possible and often advisable for drugs with significant patient populations in Quebec. Each body has its own requirements for comparators, model structure, and evidence standards — and the differences are material enough to warrant distinct modelling assumptions in some cases.

What to Do Before Phase III Results Are Even Available

The companies that navigate Canadian market access most efficiently start CADTH planning during Phase II, not after the NOC is in hand. That means aligning trial design with Canadian standard-of-care comparators where possible, collecting Canadian-relevant quality-of-life data using instruments like the EQ-5D in Canadian patient populations, and engaging Canadian patient advocacy organizations early enough to inform trial endpoint prioritization.

Building a preliminary Canadian pharmacoeconomic model in parallel with Phase III — rather than starting from scratch after filing — can compress the post-NOC preparation timeline by six months or more. CADTH publishes Optimal Use Recommendations and Drug Reimbursement Reviews across therapeutic areas that make its evidence standards explicit. Reading those before finalizing endpoints isn’t overhead; it’s risk management.

Our team regularly advises CROs and pharmaceutical sponsors on how to integrate CADTH planning into development-stage regulatory strategy. The questions that shape Canadian market access success — comparator selection, data collection instruments, patient group mapping — have clear answers early in development. They become expensive problems to solve retroactively.

If your Canadian market access strategy currently begins with the NOC celebration, it’s starting about three years too late.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Certificate of Analysis Verification and Supplier Qualification for Canadian Drug Submissions — Qalitex Laboratories provides ISO 17025-accredited analytical testing to support CADTH submission packages and Canadian drug filings.
• EU Market Authorization vs. Canadian Regulatory Pathways: A Comparative Primer for Global Sponsors — Care Europe covers EMA approval, INESSS-equivalent processes, and how European HTA submissions compare to Canada’s CDR framework.